상세 보기
Evaluating the recent developments in palliative chemotherapy for metastatic colorectal cancer
- Baek, Sun Kyung;
- Lee, Kyu Taek;
- Bae, Sang Byung;
- Lee, Sang-Cheol
Citations
WEB OF SCIENCE
3Citations
SCOPUS
5초록
The incidence of colorectal cancer (CRC) has increased. CRC is the third most common cancer and the fourth most common cause of cancer-related deaths in Korea. Palliative chemotherapy can be used to shrink tumors and ease symptoms caused by the cancer when cure is not possible. It is important to identify chemotherapeutic agents that can be used to effectively treat metastatic CRC (mCRC) and thus improve the survival and quality of life of patients with mCRC. This review aimed to evaluate the recent developments in palliative chemotherapy for mCRC and the biological or targeted agents used based on genetic alterations.
키워드
Palliative; Chemothreapy; Metastatic colorectal cancer; Survival; PHASE-III TRIAL; FLUOROURACIL PLUS LEUCOVORIN; 1ST-LINE TREATMENT; RANDOMIZED-TRIAL; RAS MUTATIONS; LIVER METASTASES; OPEN-LABEL; INFUSIONAL FLUOROURACIL; CETUXIMAB TREATMENT; ORAL CAPECITABINE
- 제목
- Evaluating the recent developments in palliative chemotherapy for metastatic colorectal cancer
- 저자
- Baek, Sun Kyung; Lee, Kyu Taek; Bae, Sang Byung; Lee, Sang-Cheol
- 발행일
- 2019-11
- 유형
- Review
- 권
- 34
- 호
- 6
- 페이지
- 1188 ~ 1196